Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food and beverage, and other key industries, will be presenting at the July 6, 2022, Emerging Growth Investor Conference. This elite event features rapidly growing public companies; each company presents a 30–45-minute overview to those in attendance. PBIO president and CEO Mr. Richard T. Schumacher will represent Pressure BioSciences at the event; his presentation, which will include a Q&A session, is slated to begin at 10:30 a.m. ET. The presentation will include information about the company’s recent announcement of the contracted production launch of its first UST-processed commercial product: a nanoemulsified CBD aerosol spray for oral use. The company invites investors, analysts and advisors to attend the session. For more than a decade, EmergingGrowth.com has been presenting these events, establishing itself as a leading, independent small-cap media portal. The conference provides unparalleled content in identifying emerging growth companies and markets that are sometimes overlooked by the investment community.
To register for and attend the event, visit https://ibn.fm/UuGB5
To view the full press release, visit https://ibn.fm/wvrj2
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating, or pressure cycling technology (“PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is on the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged for the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
